Dow Jones

50 848,75

1,86%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Replimune Group Inc (REPL)
Replimune Group Inc (REPL) Actualités

Replimune Group Inc (REPL)

8,62

0,15

(1,77%)

Fermé 12 Juin 10:00PM

8,75

0,13

(1,51%)

Après les heures de négociation: 1:56AM

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Form 4 - Statement of changes in beneficial ownership of securities

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the...

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the...

Form 8-K - Current report

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the...

Form 4 - Statement of changes in beneficial ownership of securities

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...

Form 4 - Statement of changes in beneficial ownership of securities

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

0.625% until 08.07.2032 ...

Bond 3.575% until 12.09....

Canadian Large Cap Leade...

Cyclacel Pharmaceuticals

Janus Henderson Japan Hi...

Bmo Private Us Growth Eq...

TSXV

UC Resources Ltd.

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Replimune Group Inc (REPL)

Votre Hub pour des idées et discussions en direct en temps réel